STAT Plus: The drug industry’s new tactic in Washington: calling Trump’s bluff
WASHINGTON — The pharmaceutical industry has sparred with President Trump for four years over drug pricing. Now it’s taking its biggest gamble yet: calling the president’s bluff.
The most brazen move came this week: Unlike most CEOs, who jump at the chance to visit the White House, pharmaceutical executives — newly empowered by their high-profile efforts to respond to the coronavirus and fed up with President Trump’s repeated threats — responded to his latest invitation with open contempt.
Continue to STAT Plus to read the full story…
